| Literature DB >> 34300213 |
Lorenza Burzi1, Aurora Maria Alessandrini2,3, Pietro Quaglino1, Bianca Maria Piraccini2,3, Emi Dika2,3, Simone Ribero1.
Abstract
Immunotherapy with checkpoint inhibitors significantly improves the outcome for stage III and IV melanoma. Cutaneous adverse events during treatment are often reported. We herein aim to review the principal pigmentation changes induced by immune check-point inhibitors: the appearance of vitiligo, the Sutton phenomenon, melanosis and hair and nail toxicities.Entities:
Keywords: alopecia; halo nevus; immunotherapy; melanoma; melanosis; pigmentation disorders; poliosis; vitiligo
Year: 2021 PMID： 34300213 DOI： 10.3390/jcm10143047
Source DB: PubMed Journal: J Clin Med ISSN： 2077-0383 Impact factor: 4.241